TLSI · TriSalus Life Sciences, Inc. · Executive Compensation
$3.59
-0.07 (-1.91%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. There can be no assurances that we will be successful in any of these respects, or that we will be able to continue to obtain outside capital in the future or do so on terms that are acceptable to us.”View the 10-Q filed Aug 6, 2026
Market Cap
$221.05M
Shares
61.57M
Volume · Oct 23
78.4K
Avg daily vol (3M)
261.75K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mary Szela | CEO and President | $4,823,349 |
| David B. Patience | CFO | $3,443,628 |
| David Patience | Chief Financial Officer(\ ) | $3,443,628 |
| Richard Marshak | Chief Commercial Officer | $1,556,000 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mary Szela | CEO and President | $4,136,595 |
| Sean Murphy | Manufacturing, Strategy and Business Development Officer(\ ) | $2,312,533 |
| Jodi Devlin | Chief of Clinical Operations | $1,383,741 |
| Richard Marshak | Chief Commercial Officer | $1,365,569 |
| David B. Patience | CFO | — |
| David Patience | Chief Financial Officer(\ ) | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mary Szela | CEO and President | $2,692,830 |
| Steven Katz | Chief Medical Officer | $1,613,005 |
| Sean Murphy | Manufacturing, Strategy and Business Development Officer(\ ) | $1,393,246 |
| Jodi Devlin | Chief of Clinical Operations | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Steven Katz | Chief Medical Officer | $799,146 |
| Mary Szela | CEO and President | $641,901 |
| Sean Murphy | Chief Financial Officer | $329,597 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard Marshall | Chief Medical Officer | Appointed | 2026-04-29 |
| Jodi Devlin | Chief of Clinical Operations | Retired | 2026-04-29 |
| Richard Marshall | Chief Medical Officer | Appointed | 2026-04-07 |
| Michael P. Stansky | member of the Board | Appointed | 2026-02-09 |
| Arjun "JJ" Desai | member of the Board | Resigned | 2026-02-09 |
| Sean Murphy | member of the Board and the Science and Technology Committee of the Board | Resigned | 2025-10-01 |
| David Patience | Chief Financial Officer | Appointed | 2025-05-30 |
| James Young | Chief Financial Officer | Resigned | 2025-05-30 |
| George Kelly Martin | member of the Board | Resigned | 2025-04-23 |
| Liselotte Hyveled | member of the Board, the Nominating and Corporate Governance Committee of the Board and the Science and Technology Committee of | Resigned | 2025-04-17 |
| Gary Gordon | Class III director | Appointed | 2025-01-31 |
| William Valle | Class I director | Appointed | 2025-01-31 |
| Jodi Devlin | Chief of Clinical Operations | Appointed | 2025-01-08 |
| Richard B. Marshak | Chief Commercial Officer | Appointed | 2025-01-08 |
| Sean Murphy | Chief Manufacturing, Strategy and Business Development Officer | Appointed | 2025-01-08 |
| James Young | Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer | Appointed | 2025-01-08 |
| Anil Singhal, Ph.D. | member of the Board, the Compensation Committee of the Board and the Science and Technology Committee of the Board | Resigned | 2024-11-01 |
| Liselotte Hyveled | Class I director | Appointed | 2024-05-07 |
| James "Jim" Alecxih | President, Device Technology Business | Appointed | 2023-08-16 |
| Mats Wahlström | Chairman of the New TriSalus Board | Appointed | 2023-08-16 |
| Arjun Desai | director | Appointed | 2023-08-16 |
| Kerry Hicks | director | Appointed | 2023-08-16 |
| Anil Singhal | director | Appointed | 2023-08-16 |
| George Kelly Martin | director | Appointed | 2023-08-16 |
| David J. Matlin | director | Appointed | 2023-08-16 |
Leadership
- Mary Szela CEO, Board Member
- Karim Karti Chairman
- Mats Wahlström Chairman, Board Member
- David B. Patience CFO
- David Patience CFO
- James Young CFO, Head of Investor Relations
- Andrew von Eschenbach Board Member
- Anil Singhal Board Member
- Arjun Desai Board Member
- Gary Gordon Board Member
- George Kelly Martin Board Member
- Kerry Hicks Board Member
- Liselotte Hyveled Board Member
- Manuel "Manny" Aguero Board Member
- Michael P. Stansky Board Member
- Sean Murphy Board Member
- William Valle Board Member
Key facts
CIK
1826667
CUSIP
89680M101
13F (30d)
12 filings
12 filers
Visit website
Investor relations